RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DURELLI L
Collezione AOU San Luigi di Orbassano

Items : 18

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. in Multiple sclerosis (Houndmills, Basingstoke, England) / Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

2019
AOU San Luigi di Orbassano

Lavie C; Rollot F; Durand-Dubief F; Marignier R; Ionescu I; Casey R; Moreau T; Tourniaire P; Hutchinson M; D'Hooghe MB; Laplaud DA; Clavelou P; De Sèze J; Debouverie M; Brassat D; Pelletier J; Lebrun-Frenay C; Le Page E; Castelnovo G; Berger E; Hautecoeur P; Heinzlef O; Durelli L; Clerico M; Trojano M; Patti F; Vukusic S;

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. in Multiple sclerosis (Houndmills, Basingstoke, England) / Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.

2017
AOU San Luigi di Orbassano

Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT;

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. in Journal of neuroimmunology / J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17.

2017
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Clerico M; Durelli L; Novelli F; Vladic A; Annovazzi P; Cocco E; Adamec I; Habek M; Horakova D; Bardina V; Rolla S; De Mercanti SF;

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. in Neurology(R) neuroimmunology & neuroinflammation / Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollect

2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Clerico M; Durelli L; Novelli F; Annovazzi P; Horakova D; Adamec I; Habek M; Soldo-Butkovic S; Vladic A; Cocco E; Bardina V; Cucci A; Rolla S; De Mercanti S;

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. in Journal of neurology / J Neurol. 2015 Dec;262(12):2662-7. doi: 10.1007/s00415-015-7894-1. Epub 2015 Sep 26.

2015
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Durelli L; Chio' A; Calvo A; Avagnina P; Veltri A; Cucci A; De Mercanti S; Artusi CA; Tinivella M; Busso M; Barbero P; Clerico M;

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-?. in Journal of leukocyte biology / J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5.

2014
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Durelli L; Novelli F; De Palma R; Gned D; Brusa D; Quaglino P; De Mercanti S; Bardina V; Rolla S; Clerico M;

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). in JAMA neurology / JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

2014
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Paolicelli D; Cavalla P; Sola P; Vitetta F; Realmuto S; Salemi G; Bianchi A; Ghezzi A; Lanzillo R; Brescia Morra V; Gned D; Piazza F; De Mercanti SF; Schiavetti I; Clerico M; Trojano M; Sormani MP; Durelli L;

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. in International journal of MS care / Int J MS Care. 2012 Fall;14(3):105-14. doi: 10.7224/1537-2073-14.3.105.

2012
AOU San Luigi di Orbassano

Cook SD; Dhib-Jalbut S; Dowling P; Durelli L; Ford C; Giovannoni G; Halper J; Harris C; Herbert J; Li D; Lincoln JA; Lisak R; Lublin FD; Lucchinetti CF; Moore W; Naismith RT; Oehninger C; Simon J; Sormani MP;

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose. in Journal of neuroimmunology / J Neuroimmunol. 2010 Sep 14;226(1-2):150-7. doi: 10.1016/j.jneuroim.2010.05.038. Epub 2010 Jun 23.

2010
AOU San Luigi di Orbassano

Cucci A; Barbero P; Clerico M; Ferrero B; Versino E; Contessa G; Demercanti S; Viglietta E; Di Liberto A; Vai AG; Durelli L;

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. in Annals of neurology / Ann Neurol. 2009 May;65(5):499-509. doi: 10.1002/ana.21652.

2009
AOU San Luigi di Orbassano

Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F;

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781.

2009
AOU San Luigi di Orbassano

Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M;

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. in Journal of neurology / J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.

2008
AOU San Luigi di Orbassano

Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. in Journal of neurology, neurosurgery, and psychiatry / J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51. doi: 10.1136/jnnp.2007.130229. Epub 2007 Nov 6

2008
AOU San Luigi di Orbassano

Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Rivoiro C; Ferrero C; Picco E; Ripellino P; Giuliani G; Montanari E; Clerico M; Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Rivoiro C; Ferrero C; Picco E; Ripellino P; Giuliani G; Montanari E; Clerico M;

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. in The Cochrane database of systematic reviews / Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278. doi: 10.1002/14651858.CD005278.pub3.

2008
AOU San Luigi di Orbassano

Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L;

Interferon-beta1a for the treatment of multiple sclerosis. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2007 Apr;7(4):535-42. doi: 10.1517/14712598.7.4.535.

2007
AOU San Luigi di Orbassano

Clerico M; Contessa G; Durelli L;

The importance of maintaining effective therapy in multiple sclerosis. in Journal of neurology / J Neurol. 2005 Sep;252 Suppl 3:iii38-iii43. doi: 10.1007/s00415-005-2016-0.

2005
AOU San Luigi di Orbassano

Durelli L; Clerico M;

Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy. in Frontiers in bioscience : a journal and virtual library / Front Biosci. 2004 Sep 1;9:2192-204. doi: 10.2741/1329.

2004
AOU San Luigi di Orbassano

Durelli L; Ricci A;

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. in Journal of the neurological sciences / J Neurol Sci. 2004 Jul 15;222(1-2):13-9. doi: 10.1016/j.jns.2004.03.023.

2004
AOU San Luigi di Orbassano

Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L;